Publications by authors named "Dominique Verhelle"

Claim this Profile
O
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497).
Pei-Pei Kung, Patrick Bingham, Alexei Brooun, Michael Collins, Ya-Li Deng, Dominique Verhelle

J Med Chem· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors.
Pei-Pei Kung, Eugene Rui, Simon Bergqvist, Patrick Bingham, John Braganza, Dominique Verhelle

J Med Chem· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors.
Pei-Pei Kung, Eugene Rui, Simon Bergqvist, Patrick Bingham, John Braganza, Dominique Verhelle

J Med Chem· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
Bhavatarini Vangamudi, Thomas A Paul, Parantu K Shah, Maria Kost-Alimova, Lisa Nottebaum, Dominique Verhelle

Cancer Res· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.
Anthony M Barsotti, Michael Ryskin, Wenyan Zhong, Wei-Guo Zhang, Andreas Giannakou, Dominique Verhelle

Oncotarget· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.
Laure Escoubet-Lozach, I-Lin Lin, Kristen Jensen-Pergakes, Helen A Brady, Anita K Gandhi, Dominique Verhelle

Cancer Res· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.
Laure A Moutouh-de Parseval, Dominique Verhelle, Emilia Glezer, Kristen Jensen-Pergakes, Gregory D Ferguson

J Clin Invest· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential repression of c-myc and cdc2 gene expression by ERF and PE-1/METS.
Kelly D Hester, Dominique Verhelle, Laure Escoubet-Lozach, Rosa Luna, David W Rose

Cell Cycle· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2.
Gregory D Ferguson, Kristen Jensen-Pergakes, Candice Wilkey, Urvi Jhaveri, Normand Richard, Dominique Verhelle

J Clin Immunol· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.
Dominique Verhelle, Laura G Corral, Kevin Wong, Jessica H Mueller, Laure Moutouh-de Parseval

Cancer Res· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis